November 2024—Biofidelity announced the launch of its Aspyre Lung reagents for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer biomarkers in DNA and RNA from tissue and blood in a single, four-step workflow and runs on existing qPCR platforms.
“Until now there has not been an alternative to next-generation sequencing to provide fast, simple, decentralized testing for NSCLC biomarkers,” Biofidelity cofounder and CEO Barnaby Balmforth, PhD, said in a press statement. “Aspyre Lung’s best-in-class performance from tissue and blood coupled with its proven performance with challenging samples makes simplified genomic profiling via Aspyre Lung a game changer for laboratories globally.”
The reagents are for research use only.
Biofidelity, 919-659-3285